PLSE PULSE BIOSCIENCES, INC.

NEUTRAL Impact: 3/10 8-K
Horizon months Filed Apr 9, 2026 Processed 2mo ago SEC 0001437749-26-011831
8-K context-dependent: Items 5.02, 7.01
Latest settled — T+20d
PLSE ▼ -0.21% at T+20d
NEUTRAL call ✗ call lost -0.21% · α vs SPY -7.78% · entry $19.25 → $19.21
Next anchor: T+60d in 26d
Last close $24.84 (close Jun 8) · +29.04% from $19.25 entry
Entry anchored
Apr 8, 03:59 PM ET
via Databento tick
T+1d
-3.01%
call -3.01% · α -2.95%
$18.67
settled 2mo ago
T+5d
+6.55%
call +6.55% · α +3.36%
$20.51
settled 8w ago
T+20d
-0.21%
call -0.21% · α -7.78%
$19.21
settled 5w ago
T+60d
call — · α —
in 26d

Price Chart

Loading chart...

Executive Summary

Pulse Biosciences appointed Liane Teplitsky as Chief Operating Officer and expanded Dr. David Kenigsberg's role as Chief Medical Officer to strengthen its leadership team. The company also disclosed inducement equity awards for Teplitsky and other new hires.

Actionable Insight

Monitor the company's clinical and regulatory progress under the strengthened leadership team, particularly regarding the nPulse Cardiac Catheter Ablation System development.

Key Facts

  • Appointed Liane Teplitsky as Chief Operating Officer effective April 8, 2026
  • Expanded Dr. David Kenigsberg's role to full-time Chief Medical Officer
  • Teplitsky's employment agreement includes $525,000 annual base salary and eligibility for a 70% target bonus
  • Granted inducement equity awards to Teplitsky consisting of a stock option for 700,000 shares and 200,000 restricted stock units
  • Also granted inducement options to two other recently hired employees for 7,700 shares total

Financial Impact

The inducement equity awards represent potential dilution, with Teplitsky's awards valued at approximately $13.4 million based on the $19.06 per share grant price

dilutioncompensationequity

Risk Factors

  • Potential dilution from the equity inducement awards
  • Integration risks with new executive leadership
  • Dependence on successful development of the nPulse Cardiac Catheter System

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-011831
Exhibit: ex_933283.htm0001437749-26-011831
Document: plse20260316_8k.htm0001437749-26-011831
Document: 0001437749-26-011831-index-headers.html0001437749-26-011831
Document: 0001437749-26-011831-index.html0001437749-26-011831
Document: 0001437749-26-011831.txt0001437749-26-011831
10 reports for PLSE
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+5▲ +34.22%May 11, 2026
Filters
Rows
Reports for PLSE — sortable, filterable
Type Now
May 15, 2026
25d ago
Insider Cluster
BULLISH ★ 7/10
$25.61 $26.00▲ +1.52%▼ −0.10%$24.84 (−3.01%)
May 11, 2026
4w ago
Insider Cluster
BULLISH ★ 7/10
$19.08 $25.61▲ +34.22%▲ +34.31%$24.84 (+30.19%)
May 11, 2026
4w ago
Insider Cluster
BULLISH ★ 7/10
$19.08 $25.61▲ +34.22%▲ +34.31%$24.84 (+30.19%)
May 6, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$19.21 $23.30▲ +21.29%▲ +20.16%$24.84 (+29.31%)
May 4, 2026
5w ago
8-K
MIXED ★ 6/10
$20.03 $19.08▼ −4.74%▼ −7.68%$24.84 (+24.01%)
Apr 27, 2026
6w ago
8-K
BULLISH ★ 7/10
$22.65 $20.03▼ −11.57%▼ −11.97%$24.84 (+9.67%)
Apr 16, 2026
7w ago
8-K
NEUTRAL ★ 3/10
$20.51 $24.25▲ +18.23%▲ +17.25%$24.84 (+21.11%)
Apr 9, 2026
8w ago
8-K
NEUTRAL ★ 3/10
$19.25 $20.51▲ +6.55%▲ +3.36%$24.84 (+29.04%)
Apr 7, 2026
9w ago
8-K
BULLISH ★ 7/10
$19.96 $20.12▲ +0.80%▼ −4.53%$24.84 (+24.45%)
Mar 2, 2026
14w ago
EFFECT
NEUTRAL ★ 4/10
$18.85 $18.26▼ −3.16%▼ −1.95%$24.84 (+31.78%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 6h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access